Nonbiological pharmacotherapies for the treatment of diabetic macular edema.


INTRODUCTION:During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety. The index review focuses on nonbiological therapies that have entered in phase 3 clinical trials for DME. AREAS COVERED:An extensive review of the literature was performed to identify various nonbiological immunotherapies i.e., drugs other than '-mAbs' (monoclonal antibodies including anti-VEGF agents), '-mibs' (proteasome inhibitors), '-NAbs' (nanoparticle albumin-bound), and '-nibs' (small molecule inhibitor/tyrosine kinase inhibitors), among others. Extended-release low-dose corticosteroid devices have been recently approved for the treatment of DME. Other compounds such as non-steroidal anti-inflammatory drugs, antibody mimetic proteins, nonbiological growth factor inhibitors, and inhibitors of protein kinase C have been described. EXPERT OPINION:A number of therapies are under development for the pharmacological management of DME. Due to the rising healthcare costs associated with anti-VEGF agents, a number of alternate treatment options have been explored recently. Some of these agents have reached phase 3 in clinical trials and appear to have a promising role in the management of DME. As further research is conducted, the role of each individual agent will become more defined, alone or in combination therapy.


Agarwal A,Parriott J,Demirel S,Argo C,Sepah YJ,Do DV,Nguyen QD




Has Abstract


2015-01-01 00:00:00












  • Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.

    abstract:BACKGROUND:The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with type 2 diabetes mellitus is unknown. METHODS:We conducted post hoc analyses of the results of a 52-week open-label study of Japanese type 2 diabetes mellitus patients treated with 100 or 200 ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Inagaki N,Goda M,Yokota S,Maruyama N,Iijima H

    更新日期:2015-01-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • Chemotherapeutic inhibitors in the treatment of prostate cancer.

    abstract:INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Deshmukh RR,Schmitt SM,Hwang C,Dou QP

    更新日期:2014-01-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00

  • Management of bone mineral density in HIV-infected patients.

    abstract:INTRODUCTION:Loss of bone mineral density is an emerging problem in persons living with HIV infection. Earlier and more rapid bone demineralization has been attributed not only to the high prevalence of traditional risk factors, but also to specific HIV-related factors. The aim of this guidance is to stimulate an appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Negredo E,Bonjoch A,Clotet B

    更新日期:2016-01-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论


    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Pharmacotherapeutic strategies for managing comorbid depression and diabetes.

    abstract::Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Li HQ,Chi S,Dong Q,Yu JT

    更新日期:2019-09-01 00:00:00

  • Recognition and effective management of autonomic dysreflexia in spinal cord injuries.

    abstract::Autonomic dysreflexia is a potentially life-threatening hypertensive medical emergency that occurs most often in spinal cord-injured individuals with spinal lesions at or above the mid-thoracic spinal cord level. It is a condition that remains poorly recognised outside of spinal cord injury centres, which may result i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Khastgir J,Drake MJ,Abrams P

    更新日期:2007-05-01 00:00:00

  • Therapeutic options for HIV-associated lymphomas.

    abstract:IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Spina M,Gloghini A,Tirelli U,Carbone A

    更新日期:2010-10-01 00:00:00

  • Pharmacotherapy of obstructive sleep apnea.

    abstract:INTRODUCTION:Obstructive sleep apnea syndrome is a common public health problem in the general population. The important health-related consequences of obstructive sleep apnea include cardiovascular disorders, such as myocardial infarction and hypertension, stroke, sudden death and difficult blood sugar control related...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Lin CM,Huang YS,Guilleminault C

    更新日期:2012-04-01 00:00:00

  • Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

    abstract::Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Reginster JY

    更新日期:2005-10-01 00:00:00

  • The pharmacogenetics of analgesia.

    abstract::Genomic variations influencing response to pharmacotherapy of pain are under investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules important for pharmacotherapy are discussed. Drug metabolising enzymes represent a further major target of ongoing research in order to identify assoc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Stamer UM,Stüber F

    更新日期:2007-10-01 00:00:00

  • Exemestane in postmenopausal women with early or advanced breast cancer: a review.

    abstract:IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Bertelli G,Gangadhara S

    更新日期:2010-08-01 00:00:00

  • Anti-thrombotic therapy in cancer patients.

    abstract::Primary and secondary prevention of venous thromboembolism (VTE) are the major roles of anti-thrombotic therapy in patients with cancer. Although the choices of pharmacological agents remain limited, low molecular weight heparins (LMWHs) offer important advantages over traditional anticoagulants. For prophylaxis in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Lee AY

    更新日期:2003-12-01 00:00:00

  • Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

    abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

    更新日期:2010-04-01 00:00:00

  • Anorexia in end-stage renal disease: pathophysiology and treatment.

    abstract::Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

    更新日期:2001-11-01 00:00:00

  • Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.

    abstract::Until recently, atorvastatin was known only as a new but more potent statin ('me too' drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Ray KK,Cannon CP

    更新日期:2005-06-01 00:00:00

  • Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.

    abstract::Amyotrophic [corrected] lateral sclerosis (ALS) is a progressive degenerative condition of motor neurons that is ultimately fatal. Even though scientific discovery over the past few decades has led to a greater understanding of the pathogenic mechanisms of ALS, effective pharmacotherapy intended to slow, arrest or rev...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Weiss MD,Weydt P,Carter GT

    更新日期:2004-04-01 00:00:00

  • Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.

    abstract:IMPORTANCE OF THE FIELD:Statins are widely accepted as the drugs of choice for achieving increasingly stringent low-density lipoprotein cholesterol (LDL-C) goals for dyslipidemic patients. However, when making treatment decisions, outcomes data from clinical trials are of greater importance than LDL-C-lowering ability....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Weart CW,Hogan RJ

    更新日期:2011-01-01 00:00:00

  • Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect.

    abstract::Diabetes mellitus is now occurring in epidemic proportions in many countries. Owing to the limited effectiveness of drug prophylaxis of diabetic complications after diabetes has developed, it may be more appropriate to investigate ways to prevent the onset of diabetes. A recent trial published by the Diabetes Preventi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Doggrell SA

    更新日期:2002-07-01 00:00:00

  • Seborrhoeic dermatitis: current treatment practices.

    abstract::Seborrhoeic dermatitis (SD) is a recurrent, chronic inflammation of the skin that occurs on sebum rich areas such as the face, scalp and chest, characterised by red scaly lesions. The are many studies indicating that Malassezia yeasts play an important role in the aetiology of this condition, most of the evidence for ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Gupta AK,Kogan N

    更新日期:2004-08-01 00:00:00

  • Pharmacological management of Cronkhite-Canada syndrome.

    abstract::Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Ward EM,Wolfsen HC

    更新日期:2003-03-01 00:00:00

  • Oral healthcare for HIV-infected patients: an international perspective.

    abstract::The orofacial complications of HIV infection are diverse, include opportunistic infection and malignancy and in many instances are region specific. Although effective management strategies to treat HIV-associated oral disease have been developed in North America and Europe, the evidence base on which these rely remain...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Hegarty AM,Chaudhry SI,Hodgson TA

    更新日期:2008-02-01 00:00:00

  • Current and emerging drug treatment strategies for peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Essa H,Torella F,Lip GYH

    更新日期:2020-09-01 00:00:00

  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00

  • Use of single-pill combination therapy in the evolving paradigm of hypertension management.

    abstract::The use of antihypertensive therapy is an evolving paradigm. Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clinical guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论


    authors: Calhoun DA

    更新日期:2009-08-01 00:00:00

  • Pharmacotherapy of retinal disease with visual cycle modulators.

    abstract:INTRODUCTION:Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. AREAS COVERED:...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Hussain RM,Gregori NZ,Ciulla TA,Lam BL

    更新日期:2018-04-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Recent advances in the medical therapy of Crohn's disease in childhood.

    abstract::Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Bremner AR,Beattie RM

    更新日期:2007-10-01 00:00:00

  • Pharmacological management of depression in patients with multiple sclerosis.

    abstract:INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

    更新日期:2018-10-01 00:00:00